Acute myeloid leukemia
Conditions
Interventions
Azacytidine + half dose pre excitation group:Azacytidine + half dose pre excitation
Azacytidine:Azacytidine
Sponsors
Taian Central Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Within 30 days before admission, the diagnosis and typing of newly diagnosed AML patients confirmed by morphology, immunology and genetics were based on the World Health Organization diagnosis standard (who 2018 standard); 2. Aged 60 to 75 years old) male and female; 3. ECoG physical fitness score 0-2; 4. Within 30 days before treatment, the following laboratory indexes were met: 1) total bilirubin <=1.5 ULN; 2) AST and ALT <= 2.5 ULN; 3) creatinine < 2 ULN; 5. No severe center of gravity and pulmonary dysfunction; 6. No central nervous system symptoms; 7. Do not agree to transplant; 8. The informed consent signed by the subjects or their families was obtained. The subjects or their families understood the characteristics of the disease and voluntarily joined the study program for treatment and follow-up.
Exclusion criteria
Exclusion criteria: Subjects who met any of the following criteria could not be enrolled in this study: 1. Severe heart, kidney or liver dysfunction; 2. Patients with other malignant tumors need treatment at the same time; 3. Suffer from other blood system diseases at the same time (such as hemophilia and other researchers think it is not suitable for inclusion); 4. Serious infection or metabolic diseases (including tuberculosis, pulmonary Aspergillus, etc.); 5. There are clinical symptoms of brain dysfunction or serious mental diseases that can not understand or follow the research plan; 6. People who are known to be allergic to azacytidine or any component of chemotherapy drugs 7. Within 21 days of operation with large distance; 8. AIDS patients; 9. Drug abuse, medical, psychological or social conditions that may interfere with subjects' participation in the study or evaluation of the results of the study; 10. Fail to understand or follow the research plan; 11. T (15; 17) (q22; Q12) or T (9; 22) (q34; q11.2) 12. The researchers think it is not suitable for the participants.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| OS; | — |
Countries
China
Contacts
Public ContactTeng Qingliang
Taian Central Hospital
Outcome results
None listed